{"id":24458,"date":"2025-07-25T16:44:39","date_gmt":"2025-07-25T14:44:39","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/il-crollo-brevettuale-che-minaccia-big-pharma\/"},"modified":"2025-08-01T11:10:43","modified_gmt":"2025-08-01T09:10:43","slug":"il-crollo-brevettuale-che-minaccia-big-pharma","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/","title":{"rendered":"The Patent Cliff threatening Big Pharma"},"content":{"rendered":"<p data-start=\"0\" data-end=\"55\">The Pharmaceutical Industry Enters a Critical Phase. Between 2025 and 2030, patents for more than <strong data-start=\"102\" data-end=\"128\">120 active ingredients<\/strong> are set to expire, according to an analysis by Evaluate reported in the <a href=\"https:\/\/www.ft.com\/content\/360cb65b-a9ab-4fed-b8b3-7c34f2560938?utm_source=chatgpt.com\" target=\"_blank\" rel=\"noopener\"><em data-start=\"201\" data-end=\"218\">Financial Times<\/em><\/a>. The estimated value of sales generated by these drugs exceeds <strong data-start=\"282\" data-end=\"298\">$180 billion<\/strong> \u2014 a staggering figure that is expected to shrink dramatically with the arrival of generics and biosimilars.<\/p>\n<p data-start=\"408\" data-end=\"780\" data-is-last-node=\"\" data-is-only-node=\"\">The so-called <strong data-start=\"422\" data-end=\"440\">&#8220;patent cliff&#8221;<\/strong>, already observed in the previous decade, is now returning with greater scale and complexity. Pharmaceutical companies are not only facing the expiry of numerous blockbuster patents, but they must do so in a landscape shaped by <strong data-start=\"669\" data-end=\"693\">regulatory pressures<\/strong>, <strong data-start=\"695\" data-end=\"724\">international competition<\/strong>, and a <strong data-start=\"732\" data-end=\"779\">global push to optimize healthcare spending<\/strong>.<\/p>\n<h2 data-start=\"0\" data-end=\"52\">Expiring blockbusters: names, dates, and numbers<\/h2>\n<p>Among the most significant drugs nearing patent expiry are true industry giants. Leading the list is <strong data-start=\"155\" data-end=\"167\">Keytruda<\/strong> by Merck, a flagship monoclonal antibody in immuno-oncology. In 2023, the drug generated approximately <strong data-start=\"271\" data-end=\"288\">$29.5 billion<\/strong> globally. Its U.S. patent protection is set to expire in <strong data-start=\"346\" data-end=\"354\">2028<\/strong> (<a href=\"https:\/\/www.merck.com\/news\/merck-announces-fourth-quarter-and-full-year-2024-financial-results\/?utm_source=chatgpt.com\" target=\"_blank\" rel=\"noopener\">Merck<\/a>, February 2025).<\/p>\n<p data-start=\"49\" data-end=\"331\">Another major drug approaching patent expiry is <strong data-start=\"97\" data-end=\"108\">Eliquis<\/strong> (apixaban), an anticoagulant produced by Bristol Myers Squibb and Pfizer. Its U.S. patent is set to expire in <strong data-start=\"219\" data-end=\"233\">April 2028<\/strong>, as confirmed by settlement agreements with generic manufacturers (<a href=\"https:\/\/www.bms.com\/investor-statement-on-eliquis-revenue-under-ira.html?utm_source=chatgpt.com\" target=\"_blank\" rel=\"noopener\">BMS Investor Statement, 2024<\/a>).<\/p>\n<p data-start=\"333\" data-end=\"622\"><strong data-start=\"333\" data-end=\"343\">Humira<\/strong> (adalimumab), AbbVie&#8217;s blockbuster for autoimmune diseases, <strong data-start=\"404\" data-end=\"461\">lost exclusivity in the U.S. at the beginning of 2023<\/strong>. That same year, global sales declined by approximately <strong data-start=\"518\" data-end=\"525\">32%<\/strong>, with a <strong data-start=\"534\" data-end=\"548\">45.3% drop<\/strong> in the U.S. market, according to <a href=\"https:\/\/news.abbvie.com\/2024-02-02-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2023-Financial-Results?utm_source=chatgpt.com\" target=\"_blank\" rel=\"noopener\">AbbVie\u2019s official 2023 financial report<\/a>.<\/p>\n<p data-start=\"624\" data-end=\"694\">Other high-revenue drugs nearing the end of patent protection include:<\/p>\n<ul>\n<li data-start=\"698\" data-end=\"772\"><strong data-start=\"698\" data-end=\"709\">Ibrance<\/strong> (Pfizer), with extended exclusivity until <strong data-start=\"752\" data-end=\"769\">March 5, 2027<\/strong>;<\/li>\n<li data-start=\"775\" data-end=\"881\"><strong data-start=\"775\" data-end=\"784\">Eylea<\/strong> (Regeneron and Bayer), expected to lose protection in the <strong data-start=\"843\" data-end=\"856\">2025\u20132026<\/strong> timeframe in the U.S.;<\/li>\n<li data-start=\"884\" data-end=\"1011\"><strong data-start=\"884\" data-end=\"894\">Xtandi<\/strong> (Pfizer and Astellas), with composition patents valid through <strong data-start=\"957\" data-end=\"977\">2027 in the U.S.<\/strong> and <strong data-start=\"982\" data-end=\"1010\">2026 in Europe and Japan<\/strong>.<\/li>\n<\/ul>\n<h2 data-start=\"0\" data-end=\"35\">A harsher competitive landscape<\/h2>\n<p data-start=\"37\" data-end=\"353\">In the 2000s, the first patent cliff triggered a wave of generics. Today, however, companies face an even more aggressive environment. The <strong>rise of biosimilars<\/strong> \u2014 enabled by streamlined regulations and technological advances \u2014 has intensified competition in the biologics space, once considered difficult to replicate.<\/p>\n<p data-start=\"355\" data-end=\"612\" data-is-last-node=\"\" data-is-only-node=\"\">Markets like <strong>China<\/strong> and <strong>India<\/strong> are accelerating local approvals and manufacturing, often backed by highly <strong>aggressive pricing strategies<\/strong>. This, in turn, is pushing Western healthcare systems to promote the use of equivalent products to contain public spending.<\/p>\n<h2 data-start=\"0\" data-end=\"37\">Big Pharma\u2019s defensive strategies<\/h2>\n<p data-start=\"39\" data-end=\"154\">Major pharmaceutical companies are mobilizing to avoid a collapse. Several strategic approaches are being deployed:<\/p>\n<ul data-start=\"156\" data-end=\"713\">\n<li data-start=\"156\" data-end=\"303\">\n<p data-start=\"158\" data-end=\"303\"><strong data-start=\"158\" data-end=\"186\">Mergers and acquisitions<\/strong>: Multibillion-dollar deals \u2014 such as Pfizer\u2019s acquisition of Seagen \u2014 provide fast access to innovative pipelines.<\/p>\n<\/li>\n<li data-start=\"304\" data-end=\"463\">\n<p data-start=\"306\" data-end=\"463\"><strong data-start=\"306\" data-end=\"348\">Investments in artificial intelligence<\/strong>: AI is being leveraged to accelerate drug discovery, identify more promising targets, and reduce time-to-market.<\/p>\n<\/li>\n<li data-start=\"464\" data-end=\"600\">\n<p data-start=\"466\" data-end=\"600\"><strong data-start=\"466\" data-end=\"498\">Development of \u201cbio-betters\u201d<\/strong>: Improved versions of original drugs, designed to replace blockbusters before their patents expire.<\/p>\n<\/li>\n<li data-start=\"601\" data-end=\"713\">\n<p data-start=\"603\" data-end=\"713\"><strong data-start=\"603\" data-end=\"629\">Focus on rare diseases<\/strong>: Niches with less competition and greater regulatory tolerance for premium pricing.<\/p>\n<\/li>\n<\/ul>\n<p data-start=\"715\" data-end=\"865\" data-is-last-node=\"\" data-is-only-node=\"\">In addition, companies are expanding into<strong> advanced therapeutic areas<\/strong> such as gene therapies, CAR-T, RNA-based treatments, and personalized approaches.<\/p>\n<h2 data-start=\"0\" data-end=\"35\">Regulatory pressure is mounting<\/h2>\n<p data-start=\"37\" data-end=\"397\">In the United States, the introduction of the <strong>Inflation Reduction Act<\/strong> has enabled price negotiations for certain high-impact drugs, with mechanisms that may take effect even <strong>before patent expiry<\/strong>. This marks a significant shift, potentially prompting companies to revisit their pricing and market positioning strategies as early as the second half of the 2020s.<\/p>\n<p data-start=\"399\" data-end=\"720\" data-is-last-node=\"\" data-is-only-node=\"\">At the same time, public and political pressure is growing for more equitable access to medicines \u2014 a demand that has intensified since the pandemic. The traditional justification of high prices based on R&amp;D costs is becoming less persuasive, especially when the system perceives a lack of genuine therapeutic innovation.<\/p>\n<h2 data-start=\"0\" data-end=\"29\">The Systemic Risk Is Real<\/h2>\n<p data-start=\"31\" data-end=\"400\">The threat facing Big Pharma is systemic in nature. The temporal clustering of patent expirations, combined with heavy economic reliance on a few blockbuster drugs, could lead to financial instability and loss of market capitalization. The urgent need to replace expiring products is critical, yet pipelines are not always ready, and average approval times remain high.<\/p>\n<p data-start=\"402\" data-end=\"598\" data-is-last-node=\"\" data-is-only-node=\"\">Investor and R&amp;D fund interest is also being tested: the biotech sector \u2014 often a key source of innovation for pharma \u2014 is going through a difficult cycle, with fewer IPOs and more consolidations.<\/p>\n<h2>Forced innovation: a New Era for pharmaceuticals<\/h2>\n<p data-start=\"54\" data-end=\"241\">The upcoming patent cliff is more than just an economic threat \u2014 it\u2019s a call for change. To face it, the industry must embrace a new approach: more open, more digital, more collaborative.<\/p>\n<p data-start=\"243\" data-end=\"530\" data-is-last-node=\"\" data-is-only-node=\"\">Those who manage to turn the loss of exclusivity into an <strong>opportunity for innovation<\/strong> will maintain a leading position. The others risk being pushed to the margins of a rapidly evolving ecosystem, where efficiency, speed, and clinical evidence will matter more than commercial power alone.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Between 2025 and 2030, patents on drugs worth $180 billion will expire. Big Pharma faces a historic challenge: maintaining profitability amid biosimilars, Asian competition, and new regulations. The race for innovation has only just begun.<\/p>\n","protected":false},"author":33,"featured_media":24384,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1101,796],"tags":[],"class_list":{"0":"post-24458","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-highlights-en","8":"category-market"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Patent Cliff threatening Big Pharma - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Tra il 2025 e il 2030 scadranno i brevetti di oltre 120 farmaci, per un valore stimato di 180 miliardi di dollari. Big Pharma si prepara al &quot;patent cliff&quot;.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Patent Cliff threatening Big Pharma - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Tra il 2025 e il 2030 scadranno i brevetti di oltre 120 farmaci, per un valore stimato di 180 miliardi di dollari. Big Pharma si prepara al &quot;patent cliff&quot;.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-25T14:44:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-01T09:10:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Cristiana Bernini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cristiana Bernini\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/\"},\"author\":{\"name\":\"Cristiana Bernini\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/ee100eb37b0cb2cb5a5daee9bcd05a6a\"},\"headline\":\"The Patent Cliff threatening Big Pharma\",\"datePublished\":\"2025-07-25T14:44:39+00:00\",\"dateModified\":\"2025-08-01T09:10:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/\"},\"wordCount\":776,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png\",\"articleSection\":[\"HIGHLIGHTS\",\"Market\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/\",\"name\":\"The Patent Cliff threatening Big Pharma - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png\",\"datePublished\":\"2025-07-25T14:44:39+00:00\",\"dateModified\":\"2025-08-01T09:10:43+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/ee100eb37b0cb2cb5a5daee9bcd05a6a\"},\"description\":\"Tra il 2025 e il 2030 scadranno i brevetti di oltre 120 farmaci, per un valore stimato di 180 miliardi di dollari. Big Pharma si prepara al \\\"patent cliff\\\".\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png\",\"width\":1200,\"height\":800,\"caption\":\"I farmaci in scadenza: il conto alla rovescia \u00e8 iniziato\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Patent Cliff threatening Big Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/ee100eb37b0cb2cb5a5daee9bcd05a6a\",\"name\":\"Cristiana Bernini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2f72dff643e811e45f82ed89758985ef032d7e8554f8a49e99e00ff250a44397?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2f72dff643e811e45f82ed89758985ef032d7e8554f8a49e99e00ff250a44397?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2f72dff643e811e45f82ed89758985ef032d7e8554f8a49e99e00ff250a44397?s=96&d=mm&r=g\",\"caption\":\"Cristiana Bernini\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/cristiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Patent Cliff threatening Big Pharma - MakingPharmaIndustry","description":"Tra il 2025 e il 2030 scadranno i brevetti di oltre 120 farmaci, per un valore stimato di 180 miliardi di dollari. Big Pharma si prepara al \"patent cliff\".","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/","og_locale":"en_US","og_type":"article","og_title":"The Patent Cliff threatening Big Pharma - MakingPharmaIndustry","og_description":"Tra il 2025 e il 2030 scadranno i brevetti di oltre 120 farmaci, per un valore stimato di 180 miliardi di dollari. Big Pharma si prepara al \"patent cliff\".","og_url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2025-07-25T14:44:39+00:00","article_modified_time":"2025-08-01T09:10:43+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png","type":"image\/png"}],"author":"Cristiana Bernini","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Cristiana Bernini","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/"},"author":{"name":"Cristiana Bernini","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/ee100eb37b0cb2cb5a5daee9bcd05a6a"},"headline":"The Patent Cliff threatening Big Pharma","datePublished":"2025-07-25T14:44:39+00:00","dateModified":"2025-08-01T09:10:43+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/"},"wordCount":776,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png","articleSection":["HIGHLIGHTS","Market"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/","url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/","name":"The Patent Cliff threatening Big Pharma - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png","datePublished":"2025-07-25T14:44:39+00:00","dateModified":"2025-08-01T09:10:43+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/ee100eb37b0cb2cb5a5daee9bcd05a6a"},"description":"Tra il 2025 e il 2030 scadranno i brevetti di oltre 120 farmaci, per un valore stimato di 180 miliardi di dollari. Big Pharma si prepara al \"patent cliff\".","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/07\/Il-crollo-brevettuale-che-minaccia-Big-Pharma.png","width":1200,"height":800,"caption":"I farmaci in scadenza: il conto alla rovescia \u00e8 iniziato"},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/il-crollo-brevettuale-che-minaccia-big-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"The Patent Cliff threatening Big Pharma"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/ee100eb37b0cb2cb5a5daee9bcd05a6a","name":"Cristiana Bernini","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2f72dff643e811e45f82ed89758985ef032d7e8554f8a49e99e00ff250a44397?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2f72dff643e811e45f82ed89758985ef032d7e8554f8a49e99e00ff250a44397?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2f72dff643e811e45f82ed89758985ef032d7e8554f8a49e99e00ff250a44397?s=96&d=mm&r=g","caption":"Cristiana Bernini"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/cristiana\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/24458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=24458"}],"version-history":[{"count":2,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/24458\/revisions"}],"predecessor-version":[{"id":24460,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/24458\/revisions\/24460"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/24384"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=24458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=24458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=24458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}